VVD 159642
Alternative Names: VVD-159642Latest Information Update: 09 Apr 2025
At a glance
- Originator Vividion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Feb 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Combination therapy) in USA (PO) (NCT06804824)
- 25 Feb 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Monotherapy) in USA (PO) (NCT06804824)
- 13 Feb 2025 Vividion Therapeutics plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease, Unresectable/Inoperable, Monotherapy, Combination therapy) in USA (PO, Capsule) in March 2025 (NCT06804824)